In Philadelphia in 1964, a determined young physician and virologist named Stanley Plotkin began racing to make a rubella vaccine before the next epidemic. I am not talking about the Zika virus that, as of February 2, has led to the births of at least 2,656 infants with brain damage in 28 countries. In the US, it is still produced in Hayflick's fetal cells; it is the "R" in the "MMR" vaccine given to toddlers. The NIH's inscrutable vaccine czar was silently, inveterately opposed to making vaccines in Hayflick's human fetal cells. Consider this: Late in February, 2016, then-President Obama asked Congress for $1.9 billion to fight Zika transmission and to develop a vaccine.
The speed and debilitating effects of last year's Zika outbreak in the Western Hemisphere prompted a sprint to develop a vaccine. [caption id="attachment_702874" align="alignleft" width="370"] A transmission electron micrograph of Zika virus, which is a member of the family Flaviviridae, is shown. The uncertainty poses several implications for the surge in Zika vaccine development. Michael also worries that a lag in the number of Zika cases could lead the private sector to pull funds from vaccine development. They need locations with an active viral outbreak to conduct large-scale human trials and make sure the vaccine actually protects against disease.
collected by :Lucy William
To follow all the new news about
No comments:
Post a Comment